Dyne Therapeutics CFO Lucera Sells Stock Amid Analyst Optimism and Clinical Program Updates
Erick Lucera, the Chief Financial Officer of Dyne Therapeutics, Inc., executed an automatic stock sale totaling $26,585. This transaction cleared 1,448 shares at prices averaging $18.36 per share and was related to satisfying tax withholding requirements for vested restricted stock units (RSUs). Despite this executive activity, the company continue…